¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Calcium Channel Blocking Agents"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cholinergic blocking agent
    Ç×Äݸ°¼º¾à(ù÷¡­å·), Äݸ°¼º Â÷´Ü<ºÀ¼â>Á¦.
  • competitive blocking agent
    °æÀZ(Ìæî³àõ) Â÷´ÜÁ¦(ó´Ó¨ð¥).
  • competitive blocking agent
    °æÇÕ¼º Â÷´ÜÁ¦.
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø¼º ½Å°æ±ÙºÀ¼â¾à¹°.
  • ganglionic blocking action
    ½Å°æÀýÂ÷´ÜÀÛ¿ë.
  • ganglionic blocking agent
    ½Å°æÀýÂ÷´ÜÁ¦.
  • genetic blocking
    À¯ÀüÀû Â÷´Ü(ë¶îîîÜó´Ó¨).
  • genetic blocking
    À¯ÀüÀû Â÷´Ü.
  • minimum blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • neuromuscular blocking agent
    ½Å°æ±ÙÂ÷´Ü<ºÀ¼â>Á¦(¾à).
  • neuromuscular blocking agent
    ½Å°æ±ÙÂ÷´ÜÁ¦, ½Å°æ±ÙÂ÷´Ü¾à(~ó´Ó¨å·).
  • receptor blocking agent
    ¼ö¿ëüÂ÷´Ü<ºÀ¼â>Á¦.
  • sympathetic blocking agent
    ±³°¨½Å°æÂ÷´Ü<ºÀ¼â>Á¦.
  • thought blocking
    »ç°íÂ÷´Ü(ÞÖÍÅó´Ó¨).
  • vagal blocking
    ¹ÌÁֽŰæÂ÷´Ü(¡­ó´Ó¨).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CTA Canadian Tuberculosis Association; chemotactic activity; chromotropic acid; Committee on Thrombolyti...
GBA ganglionic blocking agent; gingivobuccoaxial
ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy
NAHPA National Association of Hospital Purchasing Agents
NMBA neuromuscular blocking agent
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CICR Calcium Induced Calcium Release
CWA Chemical warfare agents
DBA Dentin bonding agents
NMBA Neuromuscular blocking agent
NSAID non steroidal anti-inflammatory agents
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • calcium levulinate
    ·¹ºÒ¸° »ê Ä®½·
    Ä®½· º¸½ÀÁ¦. ¹é»ö °áÁ¤¼º ¶Ç´Â ¹«Á¤Çü ºÐ¸¸. Ä®½· °áÇÌÁõÀÇ Ä¡·á¿¡ Ä®½· º¸±ÞÁ¦·Î »ç¿ëµÈ´Ù.
  • calcium metabolism
    Ä®½·´ë»ç
    Ç÷ÀåÁßÀÇ Ä®½· ³óµµ¸¦ ÀÏÁ¤ÇÏ°Ô À¯ÁöÇÏ¸ç »ÀÀÇ ¼®È¸È­¸¦ À§ÇÑ Ä®½· °ø±ÞÀ» ÇÏ´Â »ýÈ­ÇÐÀû, »ý¸®ÇÐÀû °úÁ¤.
  • calcium oxide
    »êÈ­ Ä®½·
    ºÎ½Ä¼º ¾ËÄ®¸®, ºÎ½Ä¼º Åä·ùÀÇ ÀÏÁ¾. °ø±âÁßÀÇ ÀÌ»êȭź¼Ò¸¦ Èí¼öÇÏ´Â µ¥ ¾²À̸ç, °ø¾÷ÀûÀ¸·Î´Â °ª½Ñ ¾ËÄ®¸®·Î ±×¸®°í ¸ð¸£Å¸¸£ÀÇ ±âÀç·Î »ç¿ëµÈ´Ù.
  • calcium phosphate
    Àλê Ä®½·
    Ä®½·±â¿Í ÀÎ»ê ±â¸¦ °¡Áø ¿°À¸·Î ¼¼ °¡Áö ÇüŰ¡ ÀÖ´Ù.
  • calcium propionate
    ÇÁ·ÎÇǿ »ê Ä®½·
    ÇÁ·ÎÇǿ »êÀÇ Ä®½·¿°. Ç× Áø±Õ¼ºÀ» °®´Â´Ù. ´Üµ¶À¸·Î ¶Ç´Â ÇÁ·ÎÇǿ »ê ³ªÆ®·ýÀ̳ª ´Ù¸¥ ¿ä¼Ò¿Í °áÇÕÇÏ¿© ¹æºÎÁ¦¿Í ±¹¼ÒÀû Ç× Áø±ÕÁ¦·Î »ç¿ëµÈ´Ù.
  • calcium pyrophosphate dihydrate
    À̼öÈ­ ÇÇ·ÎÀλê Ä®½·
  • calcium salt
    Ä®½· ¿°
  • calcium sulfate
    Ȳ»ê Ä®½·
    õ¿¬ÀûÀ¸·Î¼­ ¼®°í CaSO4, 2H2O ¹× °æ¼®°í CaSO4·Î½á »êÃâ, ÀüÀÚ¸¦ Å¿ö¼­ CaSO4, 1/2H2OÀÇ ¼Ò¼®°í·Î¼­ »ç¿ëÇÑ´Ù. À̰Ϳ¡ ¹°À» °¡ÇÏ¿© Àλóü³»¿¡ ÁÖÀÔ½ÃŰ¸é ¼öºÐ¿¡¼­ 10ºÐ »çÀÌ¿¡ ¼®°í°¡ µÇ°í °æÈ­µÈ´Ù. ¼®°íÀÇ ¿ëÇØµµ´Â 42¡É·Î¼­ ÃÖ°íÀÌ´Ù. ¼®°í ¸ðÇü Á¦ÀÛ µî¿¡ »ç¿ëµÈ´Ù.
  • calcium sulfate bonded investment
    ¼®°í°è ¸Å¸ôÀç, ¼®°í °áÇÕ ¸Å¸ôÀç
  • calcium sulfate hemihydrate
    ¹Ý¼ö ¼®°í
    À̼ö ¼®°í¸¦ °¥¾Æ¼­ 230¡­248¢µÀÇ ¿Âµµ¸¦ °¡ÇÏ¸é °áÁ¤Ã¼ ÁßÀÇ ÀϺΰ¡ »ÀÀÚ ³ª°¡ Ä¡°ú¿ë °æ¼®°í°¡ µÈ´Ù. È­ÇÐ ±¸Á¶½Ä CaSO4, 1/2H2O.
  • calcium/phosphorus metabolism
    Ä®½·/ÀÎ ´ë»ç
  • dioctyl calcium sulfosuccinate
    ¼³Æ÷È£¹Ú»ê´ÙÀÌ¿ÁÆ¿ Ä®½·
    ¹é»öÀÇ Á©¶óƾ °°Àº °íü. ¹°¿¡ ¾à°£ ³ìÀ¸¸ç ½ÀÀ±Á¦ ¹× º¯ÀÇ ¿¬È­Á¦·Î »ç¿ëµÈ´Ù.
  • exchangeable calcium
    ±³È¯¼º Ä®½·
    Á¶Á÷ ¼Ó¿¡ ÀÖÀ¸¸é¼­ Ç÷¾× »çÀÌ¿¡ »óÈ£ ±³È¯ °¡´ÉÇÑ Ä®½·.
  • milk of calcium
    ¿ìÀ¯Çü Ä®½·
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
channel protein <chemistry, physiology> A protein that facilitates the diffusion of molecules/ions across lipid membranes by forming a hydrophilic pore. most frequently multimeric with the pore formed by subunit interactions.
(18 Nov 1997)
channel transport <radiobiology> In inertial fusion research using light ion drivers, describes the use of current-carrying plasma channels (which are magnetically confined to the channel) to transport electron or ion beams between the ion diode and the fusion target. This allows the ion source to stand back from the target.
(09 Oct 1997)
chloride channel Ion channels selective for chloride ions. Various types including ligand activated Cl channels at synapses (the GABA and glycine activated channels), as well as voltage gated Cl channels found in a variety of plant and animal cells.
See: CFTR, MDR.
(18 Nov 1997)
potassium channel Ion channel selective for potassium ions. There are diverse types with different functions, for example: delayed rectifier channels, M channels, A channels, inward rectifier channels, Ca dependent K channels.
(18 Nov 1997)
single channel recording Variant of patch clamp technique.
(18 Nov 1997)
sodium channel <neurology, physiology> The protein responsible for electrical excitability of neurons. A transmembrane ion channel, containing an aqueous pore around 0.4nm diameter, with a negatively charged region internally (the selectivity filter) to block passage of anions.
The channel is voltage gated: it opens in response to a small depolarisation of the cell (usually caused by an approaching action potential), by a multistep process.
Around 1000 sodium ions pass in the next millisecond, before the channel spontaneously closes (an event with single step kinetics). The channel is then refractory to further depolarisations until returned to near the resting potential.
There are around 100 channels per square micron in unmyelinated axons, in myelinated axons, they are concentrated at the nodes of Ranvier. The sodium channel is the target of many of the deadliest neurotoxins.
(18 Nov 1997)
delayed rectifier channel <physiology> The potassium selective ion channels of axons, so called because they change the potassium conductance with a delay after a voltage step.
The name is used to denote any axon like K channel. Various roles for example regulation of pacemaker potentials, generation of bursts of action potentials or generation of long plateaus on action potentials.
(18 Nov 1997)
double-channel catheter A catheter with two lumens, allowing irrigation and aspiration.
Synonym: two-way catheter.
(05 Mar 2000)
ion channel <cell biology> A transmembrane pore that presents a hydrophilic channel for ions to cross a lipid bilayer down their electrochemical gradients.
Some degree of ion specificity is usually observed and typically a million ions per second may flow. Channels may be permanently open, like the potassium leak channel or they may be voltage gated, like the sodium channel or ligand gated like the acetylcholine receptor.
(27 Oct 1998)
ion channel gating The opening and closing of ion channels due to a stimulus. The stimulus can be a change in membrane potential (voltage-gated), drugs or chemical transmitters (ligand-gated), or a mechanical deformation. Gating is thought to involve conformational changes of the ion channel which alters selective permeability.
(12 Dec 1998)
transnexus channel A hexagonal 15-20A
ligand-gated channel A class of ion channel's whose ionic permeability is regulated by cell membrane receptors that respond to specific extracellular chemical signals.
(05 Mar 2000)
ligand gated ion channel A transmembrane ion channel whose permeability is increased by the binding of a specific ligand, typically a neurotransmitter at a chemical synapse. The permeability change is often drastic, such channels let through effectively no ions when shut, but allow passage at up to 10exp7 ions sexp 1 when a ligand is bound. Recently, the receptors for both acetylcholine and GABA have been found to share considerable sequence homology, implying that there may be a family of structurally related ligand gated ion channels.
(18 Nov 1997)
benzoylpas calcium 4-Benzamidosalicylic acid calcium salt;an antituberculous agent.
(05 Mar 2000)
calcium <element> An element taken in through the diet that is essential for a variety of bodily functions, such as neurotransmission, muscle contraction and proper heart function. Imbalances of calcium can lead to many health problems and excess calcium in nerve cells can cause their death.
(22 May 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á